#USA #Anixa Biosciences #New Orleans #CAR-T therapy #Cancer Vaccines

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference

Anixa Biosciences, Inc., a leading company in the biotechnology sector that specializes in cancer treatment and prevention, is making headlines with its upcoming presentation at the prestigious 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference, scheduled for March 27-29, 2025, at the The Roosevelt Hotel in New Orleans. Dr. Amit Kumar, the Chairman and CEO of Anixa, will present on March 28 at 10:00 AM CDT.

During his presentation, Dr. Kumar will provide an in-depth overview of Anixa's pioneering cancer treatment programs. Attendees can expect updates on the company's innovative CAR-T therapy specifically designed for solid tumors, as well as insights into their novel cancer vaccine initiatives. These groundbreaking projects underscore Anixa's commitment to advancing next-generation immunotherapies and transforming the landscape of cancer care.

The NeauxCancer Conference serves as a prime gathering for leading oncology researchers, industry executives, and healthcare professionals dedicated to discussing the latest advancements in cancer treatment. As Dr. Kumar takes the stage, attendees will gain insight into the future directions of immunotherapy and Anixa's unique approach to battling cancer.

Details of the Event

• - Event: 2025 CAGLA NeauxCancer Conference
• - Date: March 28, 2025
• - Time: 10:00 AM CDT
• - Location: The Roosevelt, New Orleans
• - Webcast: CAGLA 2025 Livestreams

About Anixa Biosciences

Founded with the mission to innovate in the field of cancer treatment and prevention, Anixa Biosciences continues to expand its clinical-stage biotechnology portfolio. The company is currently developing an ovarian cancer immunotherapy in collaboration with the esteemed Moffitt Cancer Center, employing a unique type of CAR-T therapy known as chimeric endocrine receptor-T cell (CER-T) technology. Furthermore, Anixa is working on vaccines through partnerships with the Cleveland Clinic that aim to prevent and treat cancer in women, including breast and ovarian cancers.

These vaccine programs are not just limited to breast and ovarian cancer; Anixa is also exploring additional vaccines targeting various other cancers prevalent in high-incidence malignancies such as lung, colon, and prostate cancer. The focus is set on immunizing against “retired” proteins identified in specific cancer types. This innovative approach allows Anixa Biosciences to work closely with world-class research institutions, ensuring that they leverage the latest breakthroughs in bidirectional technological advancements for drug development and commercialization.

The announcement of Dr. Kumar's presentation at the CAGLA conference is a testament to Anixa’s dedication to pushing the boundaries of cancer research and its commitment to engaging with the broader scientific and medical communities. With the evolving landscape of cancer therapies, ongoing discussions at forums like CAGLA are essential for fostering collaboration and sharing vital knowledge that could lead to transformative healthcare solutions.

For additional information about Anixa, the conference, or their innovative therapies, you can visit Anixa's Official Website or follow them on social media platforms like Twitter, LinkedIn, Facebook, and YouTube.

• ---

Forward-Looking Statements: As a gentle reminder, some of the statements made related to future expectations of Anixa may be considered forward-looking statements under federal securities laws. Such statements involve risks and uncertainties that could materially affect actual outcomes. Therefore, investors should not solely rely on these forward-looking statements when evaluating Anixa's prospects.